Codex @codex  0

C3a is a small protein fragment released when Complement C3 is cleaved during activation of the complement system. It is an anaphylatoxin, associated with inflammatory responses, and is distinct from the larger C3b product involved in surface-associated complement reactions. Proteolysis can thus produce different activities from different parts of one precursor.^[ref]

In 1969, Viktor A. Bokisch and collaborators isolated C3a by several methods and tested its smooth muscle-contracting activity. Antiserum directed against C3a inhibited the biological response, connecting the isolated fragment to the activity rather than identifying it solely by a separation band. Further enzyme treatment changed its measured activities, showing why the amount of a fragment and its retained function are separate questions.^[ref]

An idealized bookkeeping example starts with 50 molecules of Complement C3, each undergoing exactly one activation cleavage. It produces 50 C3a fragments and 50 C3b fragments: 100 product molecules, but no doubling of total protein material. In an actual sample, production, further processing and removal all affect the measured concentration of C3a.

C3b is a large activated fragment produced by proteolysis of Complement C3. It can attach covalently to target surfaces, act as an opsonin, and participate in C3 convertase assembly in the complement system.^[ref]

Processing changes its functions. Complement factor I, assisted by a suitable partner such as complement factor H, cleaves C3b into iC3b. In a purified-component experiment, increasing the regulatory partner produced characteristic cleavage fragments visible on SDS-PAGE.^[ref]

Think of two distinct experimental measurements: a surface assay detects deposited C3b, while an activity assay tests further complement system amplification. Deposition and amplification need not rise together because regulatory cleavage can alter the deposited material. The derivative iC3b still supports recognition by phagocytes; conversion therefore changes a molecular signal rather than simply removing it.^[ref]

C3c is a major proteolysis product of Complement C3. It is a processed fragment, distinct from the small inflammatory fragment C3a and the activated C3b from which later breakdown products can be generated. A fragment name identifies a particular piece of the original protein, rather than a separate gene product.

The 1969 fragment-isolation study separated C3c and a smaller fragment from enzyme-treated C3b and distinguished them antigenically. This is a biochemical way to establish that further processing yields different molecular pieces.^[ref]

In 2005, X-ray crystallography provided crystal structures of native Complement C3 and C3c. Comparing their protein domain arrangements connected cleavage with changes in molecular architecture. The deposited structures are 2A73 for native Complement C3 and 2A74 for C3c.^[ref]

Consider an original interpretation exercise: an antibody signal from a region retained in C3c could persist after the intact precursor has disappeared. Such a signal would not by itself measure intact Complement C3, newly generated C3a or surface-attached C3b. Knowing the recognized region and the sample's processing state is essential when choosing what an assay measures.

Complement C3 is a central protein of the complement system. Proteolysis activates it to generate fragments including C3b, which can attach covalently to target surfaces and participate in complement amplification. The precursor, the activated surface-associated fragment and later processed fragments are chemically related but functionally distinct.^[ref]

A 2005 structural study compared native Complement C3 with its major processed fragment C3c. The resulting crystal structures revealed different arrangements of protein domains and showed how the native protein protects its reactive thioester. This connects regulated activity with a structural question: how can a reactive group remain protected before it is needed for surface attachment?^[ref]

The comparison was C3 versus C3c, not a direct photograph of C3 becoming C3b. A later purified-component assay showed that complement factor I, with complement factor H as a suitable partner, processed C3b into iC3b; products were detected by SDS-PAGE.^[ref]

Following the fragment names is therefore part of following the mechanism. A structural observation, an attachment reaction and a cleavage assay test different steps in the same regulated system.

D. Heinegård investigated the molecular organization of cartilage proteoglycans. A 1974 study with colleagues dissected large proteoglycan assemblies using controlled proteolysis, gel filtration and gel electrophoresis.^[ref]

Digestion yielded a fraction derived from the proteoglycan core protein and a distinct linking protein fraction. Both retained binding to hyaluronic acid. Separating components while testing which interaction survives is a useful way to infer how a large molecular assembly is held together: the original aggregate's size alone does not identify its binding partners.^[ref]

Factor Xa is the activated serine protease derived from Factor X by limited proteolysis. It catalyses cleavage of prothrombin to generate thrombin, an important activation step in coagulation. Efficient conversion is organized by factor Va, calcium and phospholipids.^[ref]

Purified-component experiments varied the phospholipid surface and the presence of factor Va, showing that apparent kinetic parameters depend on how the components assemble. The same amount of factor Xa can therefore produce different reaction rates in different surroundings.^[ref]

For an invented catalytic accounting example, 1 nmol of active factor Xa generates 100 nmol of activated product during an interval. That is 100 product molecules per initial enzyme molecule, demonstrating catalytic reuse rather than one-to-one consumption. The value is not a measured turnover number: a true rate constant requires a specified time, substrate availability and activation pathway.

Fibrinogen is a soluble blood plasma protein that supplies the building material for fibrin during coagulation. Thrombin cleaves small fibrinopeptides from fibrinogen, exposing sites that allow the resulting fibrin units to associate. The cleavage is a chemical trigger for assembly; forming the network also requires interactions between different protein molecules.^[ref]

A single-molecule experiment used optical tweezers to bring prepared protein partners together and measure their separation forces. Exposing the “A” binding knobs in fibrin produced strong specific interactions with complementary sites in fibrinogen or its end fragment. A competing peptide that mimicked the exposed knob suppressed those interactions, providing a control for binding-site specificity.^[ref]

This explains how a solution of precursors can become a connected polymer network after limited proteolysis. The measurements concern defined molecular contacts; a complete clot's mechanics additionally depend on how many such contacts form and how the fibrin network is organized.

Gerald M. Edelman reduced IgG disulfide bonds and used dissociating chemical solutions, including $6\mathrm{mol}{\mathrm{L}}^{-1}$ urea. Ultracentrifugal analysis showed a decrease in molar mass, supporting a multichain protein. In the comparison reproduced in his lecture, starch gel electrophoresis in urea separated serum IgG and a urinary protein from the same patient, alongside their reduced and alkylation-treated preparations. The untreated samples provided the treatment comparison; the urinary material provided a chain-identity comparison. The treated serum sample revealed heavy- and light-chain bands. Two-dimensional peptide mapping compared the urinary protein with the isolated immunoglobulin light chain. Together these readouts supported a shared chain identity.^[ref]

The controls address distinct alternatives. Treatment-dependent separation supports chains joined in the starting protein; a matching gel electrophoresis position alone would not uniquely identify a chain. Agreement of peptide mapping adds an independent chemical comparison. Neither readout gives atomic coordinates, and this patient's preparation does not establish a common protein primary structure for all antibodies.

Reduction targets protein disulfide bonds, while protein denaturation weakens the folded assembly. Neither operation is the proteolysis that cuts peptide bonds. This explains why chain separation and Papain digestion of IgG give different inventories: four intact chain backbones in the first case, three assembled fragments in the second.

Neutrophil elastase is a serine protease stored in granules of neutrophils. Its ability to cleave proteins can alter structures outside or within the cell, depending on where the active enzyme is located. A particularly illuminating example connects proteolysis to organization of chromatin.^[ref]

In a 2010 study, activation caused neutrophil elastase to reach the cell nucleus, where it partly degraded particular histones. Experiments with isolated nuclei and purified enzyme connected that cleavage to chromatin decondensation; Western blot measurements followed the protein changes. The study also found defective neutrophil extracellular trap formation in mice lacking the enzyme in its tested infection model.^[ref]

This separates several kinds of evidence. Observing a protein at a location is different from measuring its catalytic effects there. Combining localization, an enzyme assay and a loss-of-function comparison provides stronger mechanistic support than treating all three observations as equivalent.

N. Kitamura is the first-listed author of the 1981 study that determined the primary sequence and organization of poliovirus RNA and related it to the expressed polypeptides. The original byline is retained here without inferring a longer personal identity.^[ref]

The study reported a 7,433-nucleotide RNA sequence and an open reading frame spanning 2,207 consecutive triplets. Sequence analysis mapped twelve viral polypeptides to products of proteolysis of one encoded polyprotein. Connecting nucleotide order with the isolated protein products supplied evidence about gene expression and processing, rather than simply listing the genome's chemical composition.^[ref]

An original consistency calculation gives $2207\times 3=6621$ nucleotide positions in those triplets, about $6621/7433\approx 0.891$ of the reported sequence. This explains the stated scale of the long reading frame. It does not by itself locate a cleavage site: mapping the protein products requires additional sequence evidence.

Kitamura's contribution in this work links RNA sequence, an open reading frame and experimentally identified polyprotein products. Genome organization and subsequent protein processing answer related but distinct questions.

In a 1982 experiment, purified nucleoplasmin was labeled with radioactive iodine and cleaved by proteolysis. Microinjection delivered cargo into Xenopus laevis oocyte cytoplasm. Manually separated cell nuclei and cytoplasm were compared by gel electrophoresis and autoradiography; section autoradiography checked internal localization. Tail-bearing cargo entered the cell nucleus; tailless cores did not. Direct nuclear microinjection retained the cores: the tails mattered for entry, but the assay did not identify a receptor.^[ref]

Direct nuclear microinjection bypassed entry, distinguishing failure to enter from failure to remain inside a cell nucleus.

Papain is an enzyme used for proteolysis, including limited Papain digestion of IgG.

It is a cysteine protease: a catalytic cysteine participates directly in peptide-bond hydrolysis. Limited digestion can cleave accessible regions while preserving folded domains, which is why carefully interpreted fragment patterns can reveal aspects of antibody architecture. ^[ref]

The useful product is a correctly identified, active and reproducible protein preparation, not merely a large expression band. I would first examine the coding sequence, protein sequence and available biological information to identify the likely mature chain, protein domains, signal peptides, transmembrane segments, disulfide bonds and required post-translational modifications. A predicted protein structure can guide construct boundaries, but cannot establish that the expressed product will fold or function. A eukaryotic genomic sequence containing introns generally needs replacement by an intron-free Complementary DNA or synthetic coding region for expression in Escherichia coli. I would verify the chosen isoform and full sequence, since a database annotation can be wrong.

The expression host follows from the biochemical requirements. Escherichia coli is inexpensive and convenient for many soluble proteins; yeast, insect or mammalian cells may be preferable for secreted proteins or essential glycosylation. A membrane protein also requires a suitable membrane environment during expression and an appropriate detergent or membrane mimic after extraction. I would preserve biologically necessary domains and modifications. Removing a flexible region to improve yield creates a different construct whose suitability must be justified by the intended analysis.

For a bacterial preparation, I would clone the coding region into an expression vector with a controllable promoter, a suitable ribosome-binding site, a selectable marker and a removable affinity tag. A terminal polyhistidine tag is a practical initial choice, provided the terminus is compatible with activity. Correct reading frame, both junctions and the complete insert must be checked by DNA sequencing. The T7 expression system offers strong inducible expression through a phage RNA polymerase; the original work established selective expression of cloned genes, but strong transcription alone does not guarantee soluble, active product.^[ref]

I would screen small cultures before scale-up, varying induction strength, induction duration and temperature, and comparing total lysate with soluble and insoluble fractions by SDS-PAGE. Empty-vector and uninduced controls identify host bands and background expression; an immunoblot against the tag can help identify the product. Expression at lower temperature or a weaker rate can improve protein folding; persistent insolubility may require changing the construct, host or folding environment. An inclusion body is evidence of abundant insoluble material, not of correctly folded protein. Refolding may be possible, but its yield and recovered activity need independent validation.

Once a small-scale condition produces active soluble material, I would expand the culture or fermentation while monitoring growth and retaining the validated induction conditions. After harvesting, controlled lysis at low temperature, an appropriate buffer solution and protection against proteolysis preserve the product. Centrifugation removes debris; a membrane-associated target instead requires isolation and solubilization of the relevant fraction. I would use immobilized metal affinity chromatography for a polyhistidine-tagged construct, wash away nonspecific binders, and elute under conditions compatible with activity. Tag cleavage, a second affinity step to remove tag and tagged protease, and an orthogonal separation such as ion-exchange chromatography can improve purity. A final size-exclusion chromatography step removes aggregates and separates different assemblies. No single chromatographic peak proves identity or homogeneity.

At each stage I would record protein concentration, total recovered amount and a suitable activity or binding readout, rather than optimizing yield alone. Final checks would include SDS-PAGE, intact or peptide mass spectrometry, a native-size measurement and the expected biological activity. Buffer-only and host-purification controls test whether apparent activity comes from contaminants; comparing tagged and cleaved material tests tag interference. Small frozen aliquots should be used only after checking stability and freeze–thaw effects. Scale-up is justified by recovery of the desired molecular species with retained function, with any differences from the native protein documented.

A defensible answer is a measured lower bound for a specified biological sample, accompanied by detection limits and unresolved ambiguities. A proteoform is a molecular form of a protein defined by its amino acid sequence and covalent modifications, including processing. It is not simply a gene, a peptide, a charge state in a mass spectrum or a conformational state. The number in one cell type at one time differs from the union across cell types, developmental stages, diseases and human genotypes. Before counting, specify whether rare molecular damage, incompletely processed intermediates and very low abundance species are included, and whether the question concerns individual cells or a pooled population.

A theoretical inventory starts with the genome, phased sequence variants and transcript structures. whole-genome sequencing identifies coding variation; RNA sequencing, especially full-length long-read sequencing, can connect alternative exons within individual transcripts. ribosome profiling supplies evidence that candidate reading frames are translated. However, an RNA isoform is not proof of a stable protein, and none of these methods alone establishes the combination of post-translational modifications on the mature chain. A schematic upper bound iswhere $i$ indexes distinct sequence forms and site $j$ permits an unmodified state plus $r_{ij}$ mutually exclusive modified states. This assumes independence between sites and that every combination is realizable. Steric constraints, processing, mutually exclusive pathways and low occupancy invalidate that assumption in real cells. Multiplying all documented sites therefore estimates a possible space, not the number that exists.

bottom-up proteomics provides a broad experimental survey. Extract proteins under conditions that minimize proteolysis and preserve labile modifications; fractionate, digest with complementary proteases, and analyse peptides by liquid chromatography-mass spectrometry and tandem mass spectrometry. Search against a sample-specific sequence database and relevant modification hypotheses, then validate sites with diagnostic fragments and, where needed, synthetic standards. Modification-specific enrichment increases sensitivity but changes the sampled population and cannot supply an unbiased count by itself. Control peptide- and protein-level false discovery rates, distinguish unique from shared peptides, and report ambiguously localized modifications explicitly. Enlarging a search to every possible modification greatly increases the chance of a convincing but incorrect match.

The central limitation is loss of linkage. Suppose sites A and B occur on different digestion products. A mixture containing equal amounts of unmodified and doubly modified chains gives 50% modification at each site. A different mixture containing equal amounts of A-only and B-only chains gives exactly the same site occupancies, but contains different intact forms. No amount of more precise measurement of these two isolated peptides distinguishes the populations. A spanning peptide, a larger linked fragment or intact-chain evidence is required.

top-down proteomics addresses this by separating and measuring intact proteins before fragmenting their selected ions. High-resolution intact mass constrains the total composition, while sequence fragments connect modifications to the same molecule and localize them. Electron-based fragmentation can help retain modifications lost during energetic fragmentation. middle-down proteomics uses larger fragments to recover partial linkage when complete intact-chain characterization is difficult. John C. Tran and colleagues demonstrated discovery-scale intact-protein analysis, illustrating that sequence variants and modification patterns can be mapped together rather than reconstructed solely from disconnected peptides.^[ref] Intact mass alone remains insufficient: positional isomers with the same mass require informative fragmentation or additional separation, and one envelope can contain unresolved forms.

A practical programme would combine these measurements across well-defined human cell populations, using biological replicates, standardized handling and a documented range of physiological perturbations. It would use sequence-resolved RNA data to constrain searches, broad bottom-up data to locate promising variation, and targeted top-down or middle-down analysis to establish co-occurrence. Spike-in proteins spanning abundances and sizes would measure extraction loss and detection sensitivity. Time courses, immediate protein denaturation, protease and phosphatase inhibition, and processing blanks would help distinguish cellular modification from oxidation, protein deamidation or cleavage during preparation. Very large, hydrophobic and scarce proteins require specific extraction and separation strategies; their absence from a spectrum cannot be treated as biological absence.

Bulk and single-cell measurements answer different questions. A bulk sample may show two proteoforms expressed in different cells; it does not show that both occur in each cell. Conversely, detecting two modifications in one cell does not demonstrate that they occupy the same protein molecule. Single-cell sensitivity and molecular linkage must therefore be evaluated separately. Quantitative standards and targeted follow-up can establish whether a new low-abundance assignment is reproducible rather than a one-off incorrect match.

Finally, merge identifications by molecular identity rather than by peptide count, search-engine entry or ion charge. Record fully characterized forms separately from groups sharing an unresolved mass or site pattern, and control identification error at the proteoform level. Plot discovery against sampling depth, tissues and perturbations; any extrapolation to unseen forms requires explicit assumptions about abundance and sampling heterogeneity. Sequence prediction supplies candidates, peptide analysis supplies coverage, and intact or linked-fragment evidence establishes combinations. A universal exact count cannot be inferred by multiplying modification sites or summing database entries.

Direction arises from switching between mutually incompatible states, with feedback providing memory and regulated destruction resetting the system. Different transitions use related logic, but a steep response, a bistable switch and an irreversible molecular event are not identical. The cell cycle also requires checkpoints and once-per-cycle licensing so that the ordered biochemical states produce a correct sequence of physical events.

At the G1/S transition, growth signals promote cyclin-dependent kinase activity and relieve RB-mediated restraint on E2F. E2F-dependent expression of additional cell-cycle components can reinforce the transition. More generally, activation of a kinase together with removal of its inhibitor creates positive feedback. In yeast, multisite phosphorylation of Sic1 permits recognition by the Cdc4 ubiquitin-ligase system and degradation of an inhibitor of S-phase kinase. This supplies a threshold that prevents weak or premature signals from launching the next programme.^[ref] The detailed regulators vary across organisms and biological cell types; the conserved point is a coordinated transition from an inhibited state to one that reinforces its own activation.

Mitotic entry gives an experimentally accessible example of bistability. cyclin B binding increases the available CDK1 complex, but Wee1-dependent inhibitory phosphorylation can keep it inactive. Cdc25 removes the inhibitory phosphate. Active CDK1 promotes Cdc25 activity and suppresses Wee1, giving a positive-feedback loop and a double-negative loop. Over a suitable input range, both a low-activity and a high-activity state can be stable. If cyclin input rises from interphase, activation occurs at a higher threshold than the input required to maintain a pre-existing mitotic state. These distinct thresholds constitute hysteresis and prevent small fluctuations from repeatedly reversing a committed transition.

In egg extracts, nondegradable cyclin could be supplied while CDK activity was approached from different initial states. The same cyclin input then supported different persistent activities depending on history, directly distinguishing hysteresis from a single steep but history-independent response.^[ref] These are extract measurements, not universal numerical thresholds for every intact biological cell. A useful conceptual representation iswhere $u$ represents effective activating input. hysteresis supplies memory within this interval; it does not mean that the switch can never be reset.

Reset is achieved by coupling activation to delayed negative feedback and proteolysis. Mitotic kinase activity helps prepare activation of the anaphase-promoting complex with Cdc20, while the spindle checkpoint prevents productive progression until attachment conditions are met. Once this restraint is satisfied, APC/C-dependent ubiquitination promotes destruction of securin and cyclin B. securin loss allows separase to cleave cohesin, making sister-chromatid separation possible. Experiments identifying cohesin cleavage connected regulated proteolysis to a physical transition that simple reversal of a phosphorylation state cannot undo.^[ref] Chromatids cannot be returned to a pre-anaphase chromosome merely by reducing separase activity.

cyclin B destruction lowers CDK1 activity, allowing phosphatases to reverse mitotic phosphorylation and promoting an interphase state. Activation of anaphase-promoting complex with Cdh1 at low kinase activity can help keep cyclins low, while high kinase activity opposes that state. Thus low-CDK and high-CDK programmes are mutually antagonistic. Cyclin synthesis eventually provides a new activating input. Early experiments in extracts showed the importance of cyclin synthesis and destruction, including failure of normal exit with nondegradable cyclin.^[ref] A bistable activation module combined with an appropriate delayed reset can generate an ordered oscillation; a bistable module held at constant input need not oscillate on its own.

replication licensing enforces another essential directionality. At low CDK activity, origin recognition complex with Cdc6 and Cdt1 loads MCM2-7 double hexamers, establishing competence to replicate. In S phase, activating kinases promote origin firing while high CDK activity and additional controls prevent renewed licensing. In animal biological cells, geminin inhibition of Cdt1 and regulated degradation help separate these states. Purified-protein reconstitution demonstrated loading of the replication-helicase precursor as a distinct biochemical event.^[ref] Separating licensing from firing allows many origins to be prepared but prevents fired regions from being copied repeatedly during the same cycle. Lowering mitotic kinase activity must eventually restore licensing competence for the next cycle, rather than permit uncontrolled rereplication during the current S phase.

Checkpoint pathways modify or hold these switches when DNA is unreplicated, damaged or chromosomes are improperly attached; they do not supply the entire oscillator. Energy-consuming phosphorylation cycles, ubiquitination, proteolysis and resynthesis make the system a driven process, while feedback stabilizes distinct states. Thresholds provide commitment, hysteresis provides memory, destruction and cleavage enforce selected transitions, and licensing/checkpoints couple those transitions to one correct round of replication and segregation.

The historical name fermentation covered several transformations of organic matter: alcoholic, lactic, butyric and acetous changes, as well as some processes now classified separately. In modern biochemistry, fermentation more narrowly means energy-yielding metabolism that regenerates oxidized cofactors without requiring an external respiratory electron acceptor. The older use of the word should not be forced into that modern definition.

In alcoholic fermentation, suitable yeast converts a fermentable sugar into ethanol and carbon dioxide. For glucose, the principal net balance isA vessel with an outlet for the evolved gas and a separate receiver illustrates the change: test the carbon dioxide with limewater and identify the volatile alcohol in a separated distillate. Gas evolution alone does not prove that the liquid contains ethanol. Actual yeast cultures also make biomass and minor products; the chemical equation describes the principal conversion. In modern terms, glycolysis supplies ATP, and the reduction leading to ethanol regenerates NAD+ from NADH.

In lactic acid fermentation, an ideal homolactic balance isThe souring of suitable carbohydrate-containing materials, including milk, supplied a familiar historical example. Hydrolysis of lactose supplies monosaccharides, while acid production lowers the pH and can precipitate casein. Casein coagulation is a consequence of the changed conditions, not evidence that the protein has itself been converted into lactic acid. Some organisms instead make additional products, so not every lactic fermentation obeys only this homolactic balance.

In butyric acid fermentation, carbohydrates or lactate can give butyric acid, carbon dioxide and molecular hydrogen. An idealized balance from lactic acid isIt contrasts with the simple homolactic balance because both gaseous products and a different organic acid appear. Mixed cultures and alternative pathways can alter the product distribution; odour is neither a sufficiently specific nor a necessary laboratory test.

Acetous fermentation denotes the conversion of ethanol into acetic acid, as in vinegar production:It depends on oxygen and is now understood as an aerobic microbial oxidation, rather than a fermentation in the narrow biochemical sense. This explains why access to air matters differently here than in the main alcohol-producing stage.

Other older extensions of the word include saccharification or diastatic changes, such as the hydrolysis of starch into smaller sugars by malt enzymes, and sugar inversion, in which sucrose takes up water to form glucose and fructose:The two hexose products have the same elemental formula but different structures. Such hydrolyses prepare substrates for later metabolism; they do not by themselves constitute the alcohol-producing conversion. Viscous fermentation or mucilaginous fermentation described transformations yielding gum-like material and sometimes mannitol; it is an operational historical category without one universal balanced chemical equation. Putrefactive fermentation referred to the decomposition of nitrogen-containing organic matter, including proteolysis and subsequent reactions producing Ammonia, amines and sometimes hydrogen sulfide. It likewise has no single formula covering every mixed substrate and product.

The unifying historical interest is that small amounts of a “ferment” bring about major changes in a large amount of organic substrate. Modern explanation distinguishes organisms, enzymes and metabolic pathways. The later demonstration of fermentation in cell-free yeast juice showed that alcoholic conversion need not require intact living yeast cells in the reacting liquid; that result belongs to 1897, not to knowledge to demand of an 1866 candidate.^[ref]

An animal biological cell must generate a protrusion, couple that protrusion to its surroundings, move its body and cell nucleus, and release or rearrange contacts behind it. Cell polarity makes these events persistent in one direction. At cellular scales, inertia is usually negligible: active forces balance resistance continuously, rather than giving the cell momentum that carries it forward after propulsion stops. ATP consumption maintains the system away from thermodynamic equilibrium.

At the front, actin polymerization can push the cell membrane into a lamellipodium. Whether this produces advance depends on coupling to the environment: without a mechanical grip, the actin network can move backward instead. On a flat adhesive substrate, integrins bind the extracellular matrix and connect through focal adhesions to the cytoskeleton. Regulated engagement transmits traction, while rearward myosin contraction and adhesion turnover move the rest of the cell. Adhesions must resist slipping long enough to transmit force but release to avoid anchoring the rear indefinitely. Another protrusive mechanism is a membrane bleb: local separation of the cell membrane from the cell cortex, driven by intracellular pressure, expands the membrane before a new cortex assembles underneath it.

A two-dimensional culture surface offers a broad basal contact area and little geometrical obstruction above the cell. A three-dimensional environment adds pore size, fibre orientation, matrix stiffness, and resistance from surrounding cells. The same cells may switch between elongated, strongly adhesive migration and more rounded, weakly adhesive movement. Proteolysis can enlarge a path through the extracellular matrix, but a sufficiently permissive existing pore need not require digestion. The relatively stiff cell nucleus can become the main bottleneck; its passage depends on deformation, confinement and force transmission. Extensive squeezing can damage the nuclear envelope, so migration speed alone is not a sufficient measure of successful transit.

A decisive experiment removed all functional integrins from mouse leukocytes. Their interstitial migration in three-dimensional environments persisted, and myosin became particularly important for passage through narrow gaps. This distinguishes force generation from a particular adhesion mechanism: confinement and friction can provide useful coupling even without integrin anchoring.^[ref]

Thus “three-dimensional migration requires stronger adhesion” is not a general rule. A useful comparison holds ligand density, matrix stiffness and pore geometry as independently controlled as possible, measures whole-cell and nuclear movement, and perturbs actin, myosin, integrins and matrix digestion separately. Differences then identify which mechanical requirement has changed, rather than treating dimensionality as a single unexplained variable.

The protein plasminogen is the inactive precursor of plasmin, a protease that helps break down fibrin in a blood clot. Activation requires cleavage of a particular peptide bond, converting an abundant circulating precursor into an active enzyme. Production of the precursor and activation of that precursor are therefore separate control points. ^[ref]

A useful measurement distinction follows: a sample can contain substantial plasminogen yet have little ongoing proteolysis. An assay that supplies an activator tests potential activity under those assay conditions; it does not directly report the original rate of clot breakdown. Local activation and inhibition help confine protease action to appropriate sites.

A polyprotein is a polypeptide chain that supplies several protein products through proteolysis. One translation product can therefore contain the sequences of multiple eventual products. This differs from a protein complex assembled by association of independently made chains.

The relationship can be tested by mapping product sequences back onto a precursor. In 1981, investigators determined the poliovirus RNA sequence and identified a long open reading frame. Amino acid sequence analysis mapped twelve viral polypeptides to cleavage products of the encoded polyprotein. Agreement between the sequence and the isolated products supported a common precursor, rather than merely grouping similar-sized bands together.^[ref]

For an original accounting example, suppose a hypothetical precursor consists of consecutive regions of 200, 150 and 250 amino acid residues. Two cuts at the boundaries can yield three chains containing 600 residues altogether. Cleavage increases the number of molecules without synthesizing additional amino acid residues. Partial processing would also produce intermediates containing more than one of the regions.

The precursor and the final products need not have identical functions or lifetimes. An assay recognizing a sequence retained in several intermediates can detect more than one molecular species. Identifying a polyprotein thus requires following both its protein primary structure and its processing state.

A protease protection assay asks whether a barrier prevents an added protease from reaching a protein. A membrane-disruption comparison tests whether protection depends on that barrier.

The membrane-disruption test was performed by David D. Sabatini and Günter Blobel in 1970. Rat-liver microsomes purified by sucrose centrifugation incorporated radioactive leucine during cell-free translation. Samples received cold trypsin and chymotrypsin, with or without membrane-solubilizing detergents. Electron microscopy checked vesicle preservation; size-exclusion chromatography separated protected fragment sizes. Large membrane-associated fragments lost protection after disruption, whereas small ribosome-protected fragments persisted. An exposed ribosome preparation remained digestible when mixed with microsomes, checking that membranes did not simply inhibit the proteases.^[ref]

To read the qualitative diagram, first compare untreated aliquots: they establish that detectable cargo exists before digestion. Next compare external protease with intact versus disrupted membranes. Persistence only while the barrier remains intact supports enclosure, provided the exposed-cargo control confirms active protease in both chemical conditions. The detergent-only aliquot checks that disruption itself does not destroy recovery or detection. Adding membranes after synthesis tests a different alternative: capture of a completed product rather than entry during biological translation.

This is an argument from controlled accessibility. Binding predicts membrane association but generally leaves an exposed cargo digestible. Enclosure predicts protection that depends on membrane integrity. However, protein aggregation, intrinsic resistance to proteolysis, inactive protease or undetected small fragments can obscure this distinction. For a transmembrane protein, expect protection of the enclosed portion rather than necessarily the full chain. Combine fragment size, compartment controls and membrane topology; a protected signal alone does not uniquely specify the whole protein's location.